Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs
Autore:
Chan, FKL; Sung, JJY; Ching, JYL; Wu, JCY; Lee, YT; Leung, WK; Hui, Y; Chan, LY; Lai, ACW; Chung, SCS;
Indirizzi:
Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China Chinese Univ Hong Kong Hong Kong Hong Kong Peoples R China oples R China Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China Chinese Univ Hong Kong Hong Kong Hong Kong Peoples R China oples R China
Titolo Testata:
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
fascicolo: 1, volume: 15, anno: 2001,
pagine: 19 - 24
SICI:
0269-2813(200101)15:1<19:RTOLMA>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; DOUBLE-BLIND; GASTRODUODENAL SAFETY; RHEUMATOID-ARTHRITIS; HELICOBACTER-PYLORI; COMPLICATIONS; DICLOFENAC; ULCERS; OSTEOARTHRITIS; EFFICACY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Chan, FKL Prince Wales Hosp, Dept Med & Therapeut, 30-32 Ngan Shing St, Shatin, HongKong, Peoples R China Prince Wales Hosp 30-32 Ngan Shing St Shatin Hong Kong Peoples R China
Citazione:
F.K.L. Chan et al., "Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs", ALIM PHARM, 15(1), 2001, pp. 19-24

Abstract

Background: Prophylactic misoprostol or non-steroidal anti-inflammatory drugs (NSAIDs) with low gastric toxicity (nabumetone) has been shown to reduce mucosal injury. Aim: To compare nabumetone vs. co-therapy of naproxen with low-dose misoprostol for secondary prevention of upper gastrointestinal bleeding in NSAID users. Methods: NSAID users presenting with upper gastrointestinal bleeding were enrolled if they required long-term NSAIDs. After ulcer healing, they were randomized to receive: naproxen (500-1000 mg/day) and misoprostol (200 mug b.d.), or nabumetone (1000-1500 mg/day) and placebo misoprostol for 24 weeks. The primary end-point was recurrent upper gastrointestinal bleeding. Thesecondary end-point was the proportion of patients suffering from major gastrointestinal events including ulcer bleeding, symptomatic ulcers and severe dyspepsia. Results: A total of 90 patients were included in the intention-to-treat analysis (misoprostol/naproxen 45, nabumetone 45). Recurrent bleeding occurred in 10 patients (22.2%) receiving misoprostol/naproxen compared with three(6.7%) receiving nabumetone (relative risk 3.33, 95% CI: 0.98-11.32, P=0.069). The proportion of patients suffering from major gastrointestinal events at 24 weeks was 31.1% in the misoprostol/naproxen group and 28.9% in the nabumetone group. Conclusions: Misoprostol/naproxen is not superior to nabumetone for secondary prevention of upper gastrointestinal bleeding. Neither low-dose misoprostol nor nabumetone is adequate for high-risk NSAID users.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/04/20 alle ore 06:43:05